Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 76 Show results per page	View Search Criteria \| Help With Results

	Title				Phase				Protocol IDs

	Comparing Peripheral Blood Stem Cell Transplantation Versus Bone Marrow Transplantation in Individuals With Hematologic Cancers				Phase III				418 BMTCTN-0201, NCT00075816
	Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies				Phase III				SCT 0307 NCT00619879
	Chemotherapy Followed by Allogeneic Stem Cell Transplantation in Treating Children With Hematologic Cancer				Phase II, Phase I				NCI-01-C-0125F NCT00020592
	Stem Cell Transplant for Hematologic Diseases and Renal Cell Cancer				Phase II, Phase I				H8713 NCT00058825
	Pentostatin and Donor White Blood Cells in Preventing Graft Rejection in Cancer Patients Who Have Undergone Donor Stem Cell Transplantation				Phase II, Phase I				FHCRC-1825.00 SUPERGEN-FHCRC-1825.00, NCT00096161
	Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)				Phase II, Phase I				9911M24961 MT1999-20, NCT00167219
	Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease				Phase II, Phase I				MSKCC-06125 NCT00423514
	Study of Pralatrexate and Gemcitabine With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Lymphoproliferative Malignancies				Phase II, Phase I				PDX-009 NCT00481871
	Phase I, Open-Label, Dose-Escalation, Safety and Pharmacokinetics (PK) Study of AZD4877 in Patients With Acute Myelogenous Leukemia (AML)				Phase II, Phase I				D2782C00007 NCT00486265
	Fludarabine, Busulfan, and Alemtuzumab Followed By Donor Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disease				Phase II, Phase I				BCM-H-19386 BCM-FAB, H 19386, NCT00625144


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute